(NASDAQ: ENGN) Engene Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.48%.
Engene Holdings's earnings in 2025 is -$117,302,000.On average, 12 Wall Street analysts forecast ENGN's earnings for 2025 to be -$146,113,641, with the lowest ENGN earnings forecast at -$145,731,828, and the highest ENGN earnings forecast at -$142,777,805. On average, 12 Wall Street analysts forecast ENGN's earnings for 2026 to be -$162,591,868, with the lowest ENGN earnings forecast at -$183,805,910, and the highest ENGN earnings forecast at -$132,227,721.
In 2027, ENGN is forecast to generate -$127,880,416 in earnings, with the lowest earnings forecast at -$158,860,822 and the highest earnings forecast at -$84,400,673.